reuters : declared in Clovis's ovarian cancer drug wins accelerated FDA approval
This was collected by Lucy William
follow all the new news about Drug
image uploaded by "reuters" site
A view shows the U.S. Food and addiction Administration (FDA) headquarters in Silver Spring, Maryland August 14, 2012.REUTERS/Jason Reed/File PhotoThe U.S. Food and Drug Administration granted accelerated approval to Clovis Oncology Inc's ovarian cancer drug in patients with a specific gene mutation whose disease had advanced despite two or more rounds of chemotherapy.The drug, rubraca, which secured approval about two months earlier than scheduled, targets patients whose tumors have a mutation called BRCA, identifiable using an FDA-approved companion diagnostic test.
about the details read more from here
image uploaded by "telegraph" site
A treatment for prostate cancer based on bacteria which live on the ocean floor brings complete remission for half of patients, a new trial has shown.The therapy, involves injecting a light sensitive drug into the bloodstream and activating it with a drug to destroy tumour tissue, while leaving healthy tissue unharmed.The research, published in The Lancet Oncology, found that around half (49 per cent) of 413 patients with low-risk prostate cancer treated went into complete remission compared with 13.5 per cent in the control group who were given no treatment.
about the details read more from here
image uploaded by "cnbc" site
Shares of Clovis Oncology closed up 8.82 percent Monday as the company received early approval for its advanced ovarian cancer drug Rubraca (rucaparib).The stock was initially up 15 percent to $42.86 before being halted for volatility.After reopening, it continued to climb and jumped as much as 22 percent before paring its gains and finishing the day up less than 9 percent.
about the details read more from here
image uploaded by "theguardian" site
A drug activated by laser light successfully destroys early prostate cancer while avoiding side-effects that commonly occur with surgery, trial results have shown.The new technique, called vascular-targeted photodynamic therapy (VTP), involves injecting a light-sensitive drug into the bloodstream.The drug is then "switched on" by laser pulses fired through optical fibres inserted into the prostate.
about the details read more from here
We will quote to you the news of the best health sites Like : "reuters" and the most famous medical experts : Reuters Editorial
daily : 2016-12-20 & on time : 2:36
follow all the new news about Drug
as mentioned in
Clovis's ovarian cancer drug wins accelerated FDA approval
image uploaded by "reuters" site
A view shows the U.S. Food and addiction Administration (FDA) headquarters in Silver Spring, Maryland August 14, 2012.REUTERS/Jason Reed/File PhotoThe U.S. Food and Drug Administration granted accelerated approval to Clovis Oncology Inc's ovarian cancer drug in patients with a specific gene mutation whose disease had advanced despite two or more rounds of chemotherapy.The drug, rubraca, which secured approval about two months earlier than scheduled, targets patients whose tumors have a mutation called BRCA, identifiable using an FDA-approved companion diagnostic test.
about the details read more from here
Prostate cancer drug based on sea-bed bacteria brings complete remission for half of patients
image uploaded by "telegraph" site
A treatment for prostate cancer based on bacteria which live on the ocean floor brings complete remission for half of patients, a new trial has shown.The therapy, involves injecting a light sensitive drug into the bloodstream and activating it with a drug to destroy tumour tissue, while leaving healthy tissue unharmed.The research, published in The Lancet Oncology, found that around half (49 per cent) of 413 patients with low-risk prostate cancer treated went into complete remission compared with 13.5 per cent in the control group who were given no treatment.
about the details read more from here
Clovis Oncology spikes; receives early FDA approval for advanced cancer drug
image uploaded by "cnbc" site
Shares of Clovis Oncology closed up 8.82 percent Monday as the company received early approval for its advanced ovarian cancer drug Rubraca (rucaparib).The stock was initially up 15 percent to $42.86 before being halted for volatility.After reopening, it continued to climb and jumped as much as 22 percent before paring its gains and finishing the day up less than 9 percent.
about the details read more from here
Laser-activated drug a 'leap forward' for prostate cancer treatment
image uploaded by "theguardian" site
A drug activated by laser light successfully destroys early prostate cancer while avoiding side-effects that commonly occur with surgery, trial results have shown.The new technique, called vascular-targeted photodynamic therapy (VTP), involves injecting a light-sensitive drug into the bloodstream.The drug is then "switched on" by laser pulses fired through optical fibres inserted into the prostate.
about the details read more from here
Comments
Post a Comment